Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
Martin Reck, Igor Bondarenko, Alexander Valerievich Luft et al. · Annals of Oncology · 2012
Cited by 611 works. doi:10.1093/annonc/mds213 Open-access PDF
Authors
- Martin Reck
- Igor Bondarenko
- Alexander Valerievich Luft
- Piotr Serwatowski
- Fabrice Barlési
- Raju Titus Chacko
- Martin Sebastian
- Huiling Lü
- Jean-Marie Cuillerot
- Thomas James Lynch
References
- Reporting results of cancer treatment
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
- Enhancement of Antitumor Immunity by CTLA-4 Blockade
- CTLA-4 can function as a negative regulator of T cell activation
- A Confidence Interval for the Median Survival Time